Online inquiry

IVTScrip™ mRNA-Anti-PVRL4, AGS-22CE(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1981MR)

This product GTTS-WQ1981MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets PVRL4 gene. The antibody can be applied in Bladder Cancer research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_030916.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 81607
UniProt ID Q96NY8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PVRL4, AGS-22CE(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ1981MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5369MR IVTScrip™ mRNA-Anti-env, CD4(178) PE40(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CD4(178) PE40
GTTS-WQ1698MR IVTScrip™ mRNA-Anti-Dabigatran, aDabi-Fab(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA aDabi-Fab
GTTS-WQ10457MR IVTScrip™ mRNA-Anti-SOST, LY2541546(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA LY2541546
GTTS-WQ2019MR IVTScrip™ mRNA-Anti-INSR, AGT-181(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA AGT-181
GTTS-WQ12945MR IVTScrip™ mRNA-Anti-MUC1, PankoMab(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA PankoMab
GTTS-WQ9993MR IVTScrip™ mRNA-Anti-env, KD-247(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA KD-247
GTTS-WQ8729MR IVTScrip™ mRNA-Anti-CCR5, HuPRO-140(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA HuPRO-140
GTTS-WQ11056MR IVTScrip™ mRNA-Anti-EGFR&LGR5, MCLA-158(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MCLA-158
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW